Literature DB >> 21984601

Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease.

Giuseppa Mudò1, Johanna Mäkelä, Valentina Di Liberto, Timofey V Tselykh, Melania Olivieri, Petteri Piepponen, Ove Eriksson, Annika Mälkiä, Alessandra Bonomo, Minna Kairisalo, Jose A Aguirre, Laura Korhonen, Natale Belluardo, Dan Lindholm.   

Abstract

Mitochondrial dysfunction and oxidative stress occur in Parkinson's disease (PD), but little is known about the molecular mechanisms controlling these events. Peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α) is a transcriptional coactivator that is a master regulator of oxidative stress and mitochondrial metabolism. We show here that transgenic mice overexpressing PGC-1α in dopaminergic neurons are resistant against cell degeneration induced by the neurotoxin MPTP. The increase in neuronal viability was accompanied by elevated levels of mitochondrial antioxidants SOD2 and Trx2 in the substantia nigra of transgenic mice. PGC-1α overexpression also protected against MPTP-induced striatal loss of dopamine, and mitochondria from PGC-1α transgenic mice showed an increased respiratory control ratio compared with wild-type animals. To modulate PGC-1α, we employed the small molecular compound, resveratrol (RSV) that protected dopaminergic neurons against the MPTP-induced cell degeneration almost to the same extent as after PGC-1α overexpression. As studied in vitro, RSV activated PGC-1α in dopaminergic SN4741 cells via the deacetylase SIRT1, and enhanced PGC-1α gene transcription with increases in SOD2 and Trx2. Taken together, the results reveal an important function of PGC-1α in dopaminergic neurons to combat oxidative stress and increase neuronal viability. RSV and other compounds acting via SIRT1/PGC-1α may prove useful as neuroprotective agents in PD and possibly in other neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984601     DOI: 10.1007/s00018-011-0850-z

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  45 in total

1.  Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain.

Authors:  Rita Marie Cowell; Kathryn Rose Blake; James W Russell
Journal:  J Comp Neurol       Date:  2007-05-01       Impact factor: 3.215

2.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

3.  Neuroprotection by resveratrol against traumatic brain injury in rats.

Authors:  Ozkan Ates; Suleyman Cayli; Eyup Altinoz; Iclal Gurses; Neslihan Yucel; Metin Sener; Ayhan Kocak; Saim Yologlu
Journal:  Mol Cell Biochem       Date:  2006-08-19       Impact factor: 3.396

4.  Resveratrol stimulates AMP kinase activity in neurons.

Authors:  Biplab Dasgupta; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-16       Impact factor: 11.205

5.  PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload.

Authors:  Zhongbing Lu; Xin Xu; Xinli Hu; John Fassett; Guangshuo Zhu; Yi Tao; Jingxin Li; Yimin Huang; Ping Zhang; Baolu Zhao; Yingjie Chen
Journal:  Antioxid Redox Signal       Date:  2010-10-01       Impact factor: 8.401

Review 6.  Overexpression of growth-associated proteins in the neurons of adult transgenic mice.

Authors:  P Caroni
Journal:  J Neurosci Methods       Date:  1997-01       Impact factor: 2.390

7.  The novel cyclooxygenase-2 inhibitor GW637185X protects against l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.

Authors:  Jose A Aguirre; Giuseppina Leo; Raquel Cueto; Beth Andbjer; Alan Naylor; Andrew D Medhurst; Luigi F Agnati; Kjell Fuxe
Journal:  Neuroreport       Date:  2008-04-16       Impact factor: 1.837

8.  Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity.

Authors:  Jianfei Chao; Man-Shan Yu; Yuen-Shan Ho; Mingfu Wang; Raymond Chuen-Chung Chang
Journal:  Free Radic Biol Med       Date:  2008-07-16       Impact factor: 7.376

9.  PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons.

Authors:  Przemyslaw Wareski; Annika Vaarmann; Vinay Choubey; Dzhamilja Safiulina; Joanna Liiv; Malle Kuum; Allen Kaasik
Journal:  J Biol Chem       Date:  2009-06-19       Impact factor: 5.157

10.  Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation.

Authors:  Thomas Dehmer; Michael T Heneka; Magdalena Sastre; Johannes Dichgans; Jörg B Schulz
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

View more
  129 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  PGC-1α: a master gene that is hard to master.

Authors:  Dan Lindholm; Ove Eriksson; Johanna Mäkelä; Natale Belluardo; Laura Korhonen
Journal:  Cell Mol Life Sci       Date:  2012-06-09       Impact factor: 9.261

Review 3.  Are sirtuins viable targets for improving healthspan and lifespan?

Authors:  Joseph A Baur; Zoltan Ungvari; Robin K Minor; David G Le Couteur; Rafael de Cabo
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

4.  Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.

Authors:  Saurav Brahmachari; Saebom Lee; Sangjune Kim; Changqing Yuan; Senthilkumar S Karuppagounder; Preston Ge; Rosa Shi; Esther J Kim; Alex Liu; Donghoon Kim; Stephan Quintin; Haisong Jiang; Manoj Kumar; Seung Pil Yun; Tae-In Kam; Xiaobo Mao; Yunjong Lee; Deborah A Swing; Lino Tessarollo; Han Seok Ko; Valina L Dawson; Ted M Dawson
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

Review 5.  Gene therapy targeting mitochondrial pathway in Parkinson's disease.

Authors:  Chi-Jing Choong; Hideki Mochizuki
Journal:  J Neural Transm (Vienna)       Date:  2016-09-16       Impact factor: 3.575

6.  PPAR Gamma Coactivator 1 Beta (PGC-1β) Reduces Mammalian Target of Rapamycin (mTOR) Expression via a SIRT1-Dependent Mechanism in Neurons.

Authors:  Ying-Chun Liu; Xiao-Xiao Gao; Zhi-Guang Zhang; Zhao-Hua Lin; Qi-Lian Zou
Journal:  Cell Mol Neurobiol       Date:  2016-09-15       Impact factor: 5.046

7.  AUTOPHAGY, MITOCHONDRIAL DYNAMICS AND RETINAL DISEASES.

Authors:  Talia R Kaden; Wei Li
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2013 Sep-Oct

8.  Donepezil attenuates injury following ischaemic stroke by stimulation of neurogenesis, angiogenesis, and inhibition of inflammation and apoptosis.

Authors:  Arian Madani Neishaboori; Solmaz Nasseri Maleki; Mahdi Saberi Pirouz; Sara Golmohammadi; Donya Nazarinia; Nahid Aboutaleb
Journal:  Inflammopharmacology       Date:  2020-11-17       Impact factor: 4.473

Review 9.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

Review 10.  Does PGC1α/FNDC5/BDNF Elicit the Beneficial Effects of Exercise on Neurodegenerative Disorders?

Authors:  Mohammad Jodeiri Farshbaf; Kamran Ghaedi; Timothy L Megraw; Jennifer Curtiss; Mahsa Shirani Faradonbeh; Pooneh Vaziri; Mohammad Hossein Nasr-Esfahani
Journal:  Neuromolecular Med       Date:  2015-11-26       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.